Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence
The treatment of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis (TB) remains a challenge for clinicians for several reasons, including the large number of drugs required, the cost, the tolerability of single drugs and their combinations, and the effectiveness and long tre...
Gespeichert in:
| Veröffentlicht in: | The European respiratory journal 2017-11, Vol.50 (5), p.1701462-1701462 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1701462 |
|---|---|
| container_issue | 5 |
| container_start_page | 1701462 |
| container_title | The European respiratory journal |
| container_volume | 50 |
| creator | Pontali, Emanuele Sotgiu, Giovanni Tiberi, Simon D'Ambrosio, Lia Centis, Rosella Migliori, Giovanni B |
| description | The treatment of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis (TB) remains a challenge for clinicians for several reasons, including the large number of drugs required, the cost, the tolerability of single drugs and their combinations, and the effectiveness and long treatment duration [1–6]. Therefore, fresh attention has recently been paid to new and repurposed anti-TB drugs [4, 5, 7–18]. |
| doi_str_mv | 10.1183/13993003.01462-2017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1966236756</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1984381815</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-b42b1dae50901b57f2dc65366b017d5c33a89c33782ccebf0d2308ce12e80ad43</originalsourceid><addsrcrecordid>eNpdkE1LxDAQhoMo7rr6CwQpePHSNcm0aepNFr9gQQQ9lzSZYpZ-7Cat0H9vqrsevCSZ4XmHyUPIJaNLxiTcMshzoBSWlCWCx5yy7IjMp248tY_JnOYUYpaDmJEz7zeUMpEAOyUznoeIoOmcvK2UM1bpyKsK-zHqqqhEo3aDrW2Ld5GK_Oh7bFRvdaRaE2lnw1PVoVD16K2fIv0nRvhlDbYaz8lJpWqPF_t7QT4eH95Xz_H69elldb-ONWSyj8uEl8woTMOSrEyzihstUhCiDP8wqQZQMg9nJrnWWFbUcKBSI-MoqTIJLMjN79yt63YD-r5orNdY16rFbvAFy4XgILJUBPT6H7rpBhf2nyiZgGSSpYGCX0q7znuHVbF1tlFuLBgtJuPFwXjxY7yYjIfU1X72UDZo_jIHxfAN_Dp6Og</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1984381815</pqid></control><display><type>article</type><title>Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Pontali, Emanuele ; Sotgiu, Giovanni ; Tiberi, Simon ; D'Ambrosio, Lia ; Centis, Rosella ; Migliori, Giovanni B</creator><creatorcontrib>Pontali, Emanuele ; Sotgiu, Giovanni ; Tiberi, Simon ; D'Ambrosio, Lia ; Centis, Rosella ; Migliori, Giovanni B</creatorcontrib><description>The treatment of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis (TB) remains a challenge for clinicians for several reasons, including the large number of drugs required, the cost, the tolerability of single drugs and their combinations, and the effectiveness and long treatment duration [1–6]. Therefore, fresh attention has recently been paid to new and repurposed anti-TB drugs [4, 5, 7–18].</description><identifier>ISSN: 0903-1936</identifier><identifier>EISSN: 1399-3003</identifier><identifier>DOI: 10.1183/13993003.01462-2017</identifier><identifier>PMID: 29146605</identifier><language>eng</language><publisher>England: European Respiratory Society Journals Ltd</publisher><subject>Antitubercular Agents - administration & dosage ; Antitubercular Agents - adverse effects ; Diarylquinolines - administration & dosage ; Diarylquinolines - adverse effects ; Electrocardiography ; Heart diseases ; Humans ; Long QT Syndrome - chemically induced ; Long QT Syndrome - diagnosis ; Multidrug resistance ; Tuberculosis ; Tuberculosis, Multidrug-Resistant - drug therapy</subject><ispartof>The European respiratory journal, 2017-11, Vol.50 (5), p.1701462-1701462</ispartof><rights>Copyright European Respiratory Society Journals Ltd. Nov 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-b42b1dae50901b57f2dc65366b017d5c33a89c33782ccebf0d2308ce12e80ad43</citedby><cites>FETCH-LOGICAL-c378t-b42b1dae50901b57f2dc65366b017d5c33a89c33782ccebf0d2308ce12e80ad43</cites><orcidid>0000-0002-2597-574X ; 0000-0002-1600-4474</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29146605$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pontali, Emanuele</creatorcontrib><creatorcontrib>Sotgiu, Giovanni</creatorcontrib><creatorcontrib>Tiberi, Simon</creatorcontrib><creatorcontrib>D'Ambrosio, Lia</creatorcontrib><creatorcontrib>Centis, Rosella</creatorcontrib><creatorcontrib>Migliori, Giovanni B</creatorcontrib><title>Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence</title><title>The European respiratory journal</title><addtitle>Eur Respir J</addtitle><description>The treatment of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis (TB) remains a challenge for clinicians for several reasons, including the large number of drugs required, the cost, the tolerability of single drugs and their combinations, and the effectiveness and long treatment duration [1–6]. Therefore, fresh attention has recently been paid to new and repurposed anti-TB drugs [4, 5, 7–18].</description><subject>Antitubercular Agents - administration & dosage</subject><subject>Antitubercular Agents - adverse effects</subject><subject>Diarylquinolines - administration & dosage</subject><subject>Diarylquinolines - adverse effects</subject><subject>Electrocardiography</subject><subject>Heart diseases</subject><subject>Humans</subject><subject>Long QT Syndrome - chemically induced</subject><subject>Long QT Syndrome - diagnosis</subject><subject>Multidrug resistance</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><issn>0903-1936</issn><issn>1399-3003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE1LxDAQhoMo7rr6CwQpePHSNcm0aepNFr9gQQQ9lzSZYpZ-7Cat0H9vqrsevCSZ4XmHyUPIJaNLxiTcMshzoBSWlCWCx5yy7IjMp248tY_JnOYUYpaDmJEz7zeUMpEAOyUznoeIoOmcvK2UM1bpyKsK-zHqqqhEo3aDrW2Ld5GK_Oh7bFRvdaRaE2lnw1PVoVD16K2fIv0nRvhlDbYaz8lJpWqPF_t7QT4eH95Xz_H69elldb-ONWSyj8uEl8woTMOSrEyzihstUhCiDP8wqQZQMg9nJrnWWFbUcKBSI-MoqTIJLMjN79yt63YD-r5orNdY16rFbvAFy4XgILJUBPT6H7rpBhf2nyiZgGSSpYGCX0q7znuHVbF1tlFuLBgtJuPFwXjxY7yYjIfU1X72UDZo_jIHxfAN_Dp6Og</recordid><startdate>201711</startdate><enddate>201711</enddate><creator>Pontali, Emanuele</creator><creator>Sotgiu, Giovanni</creator><creator>Tiberi, Simon</creator><creator>D'Ambrosio, Lia</creator><creator>Centis, Rosella</creator><creator>Migliori, Giovanni B</creator><general>European Respiratory Society Journals Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2597-574X</orcidid><orcidid>https://orcid.org/0000-0002-1600-4474</orcidid></search><sort><creationdate>201711</creationdate><title>Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence</title><author>Pontali, Emanuele ; Sotgiu, Giovanni ; Tiberi, Simon ; D'Ambrosio, Lia ; Centis, Rosella ; Migliori, Giovanni B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-b42b1dae50901b57f2dc65366b017d5c33a89c33782ccebf0d2308ce12e80ad43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antitubercular Agents - administration & dosage</topic><topic>Antitubercular Agents - adverse effects</topic><topic>Diarylquinolines - administration & dosage</topic><topic>Diarylquinolines - adverse effects</topic><topic>Electrocardiography</topic><topic>Heart diseases</topic><topic>Humans</topic><topic>Long QT Syndrome - chemically induced</topic><topic>Long QT Syndrome - diagnosis</topic><topic>Multidrug resistance</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pontali, Emanuele</creatorcontrib><creatorcontrib>Sotgiu, Giovanni</creatorcontrib><creatorcontrib>Tiberi, Simon</creatorcontrib><creatorcontrib>D'Ambrosio, Lia</creatorcontrib><creatorcontrib>Centis, Rosella</creatorcontrib><creatorcontrib>Migliori, Giovanni B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The European respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pontali, Emanuele</au><au>Sotgiu, Giovanni</au><au>Tiberi, Simon</au><au>D'Ambrosio, Lia</au><au>Centis, Rosella</au><au>Migliori, Giovanni B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence</atitle><jtitle>The European respiratory journal</jtitle><addtitle>Eur Respir J</addtitle><date>2017-11</date><risdate>2017</risdate><volume>50</volume><issue>5</issue><spage>1701462</spage><epage>1701462</epage><pages>1701462-1701462</pages><issn>0903-1936</issn><eissn>1399-3003</eissn><abstract>The treatment of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis (TB) remains a challenge for clinicians for several reasons, including the large number of drugs required, the cost, the tolerability of single drugs and their combinations, and the effectiveness and long treatment duration [1–6]. Therefore, fresh attention has recently been paid to new and repurposed anti-TB drugs [4, 5, 7–18].</abstract><cop>England</cop><pub>European Respiratory Society Journals Ltd</pub><pmid>29146605</pmid><doi>10.1183/13993003.01462-2017</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-2597-574X</orcidid><orcidid>https://orcid.org/0000-0002-1600-4474</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0903-1936 |
| ispartof | The European respiratory journal, 2017-11, Vol.50 (5), p.1701462-1701462 |
| issn | 0903-1936 1399-3003 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1966236756 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Antitubercular Agents - administration & dosage Antitubercular Agents - adverse effects Diarylquinolines - administration & dosage Diarylquinolines - adverse effects Electrocardiography Heart diseases Humans Long QT Syndrome - chemically induced Long QT Syndrome - diagnosis Multidrug resistance Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy |
| title | Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T16%3A55%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiac%20safety%20of%20bedaquiline:%20a%20systematic%20and%20critical%20analysis%20of%20the%20evidence&rft.jtitle=The%20European%20respiratory%20journal&rft.au=Pontali,%20Emanuele&rft.date=2017-11&rft.volume=50&rft.issue=5&rft.spage=1701462&rft.epage=1701462&rft.pages=1701462-1701462&rft.issn=0903-1936&rft.eissn=1399-3003&rft_id=info:doi/10.1183/13993003.01462-2017&rft_dat=%3Cproquest_cross%3E1984381815%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1984381815&rft_id=info:pmid/29146605&rfr_iscdi=true |